DESTINY-Breast03 Phase 3 Study Results
Background
Cadherin 6 (CDH6) is part of the cadherin family,
which is involved with cell-cell adhesion, organ
development, and epithelial-mesenchymal transition
CDH6 is found to be overexpressed in various
cancers, particularly ovarian cancer (OVC) and renal
cell carcinoma (RCC) 1
In preclinical studies, DS-6000a inhibited tumor
growth and induced tumor regression in CDH6-
expressing OVC and RCC1
Here, we report initial results from the dose-
escalation portion of a first-in-human trial in patients.
with advanced OVC and RCC (NCT04707248)
PDX, patient-derived xenograft.
1. Hirokazu S, et al. ESMO 2021. Abstract 10P.
ASCO 2022 #3002 Oral
Tumor volume, mm³
H score
100
200
300
CDH6 Expression in RCC/Serous OVC1
Clear cell RCC Papillary RCC Serous OVC
Antitumor Activity of DS-6000a
in RCC and OVC PDX Model¹
1400
CDH6
RCC
1200
1000
800
Vehicle
600
400
DS-6000a
200
0
0
20
40
40
Day
Tumor volume, mm³
Median
1200
CDH6
OVC
1000
800
Vehicle
600
400
200
DS-6000a
0
0
20
40
Day
97
Daiichi-SankyoView entire presentation